Orca Bio’s Post

Carcinomas account for ~90% of cancers. This is why the recent FDA approval of TIL therapy is changing the field of cell therapy. In this podcast, Jason Bock talks with Daniel Levine about this achievement and what is on the horizon with the brilliant next generation TILs in development and in the clinic. #biotech #celltherapy #TILtherapy #endcancer https://lnkd.in/et-A5hUe

The challenge of enhancing the effectiveness and durability of engineered lymphocyte therapies is one of the key issues in the field of #lymphocyte engineering and cell therapy. The topic will be discussed in detail by top experts – Michel Sadelain, Univ.-Prof. Dr. med. Marion Subklewe and Jennifer Brogdon during the 1st session of #ICLE2025 – “Real-world experience, novel clinical approaches and combination therapies.” The session will aim to explore the potential synergy between engineered lymphocytes and other treatment modalities. Dive into the program to find out what else to expect: https://bit.ly/4bK8Gm2 #lymphocytes #lymphocytesengineering #CARTcells

Mustang Bio to Begin Phase I Trial of Oncolytic Virus, Cell Therapy Combo in Glioblastoma. The trial will evaluate the combination in patients with IL13Rα2-expressing glioblastoma and astrocytoma. http://ow.ly/oOUy104Zgoc

Discover how to engineer and analyze CAR-T cell signaling and activation using cutting-edge tools in our upcoming webinar. Learn from experts about innovative non-viral editing and analytical platforms that enhance CAR-T cell therapy efficiency. #CARTTherapy #GeneEditing #CancerResearch https://lnkd.in/gaQq5EVi

🔍 Join our upcoming webinar to explore the latest advancements in CAR-T cell signaling and activation. Gain insights from leading experts on innovative non-viral editing 🧬 and analytical platforms that are revolutionizing the efficiency of CAR-T cell therapy. 🌟

⏰ Save The Date - 27th June ⏰ Join our upcoming webinar featuring a panel discussion on methods of streamlining the CAR-T workflow. As CAR-T cell therapy continues to advance it's important to address the challenges that come with it. One key issue is the manufacturing process, which can be costly and time-consuming. That's why efforts to create a more efficient CAR-T cell therapy manufacturing process are crucial. Join this webinar to learn more about the analytical tools that are contributing to these advancements! #celltherapy #CART

We’re 🤯 by the latest clinical trial research from Oncologie | UNIL-CHUV! Read our blog to see how they used #singlecell technologies to characterize the tumor-immune features that could be the key to successful adoptive cell therapy in metastatic #melanoma.

Autologous CAR-T cell therapies are going to revolutionize cancer treatment. Flow cytometry is a critical analytical tool for cell therapy development. In this blog, read how automation and standardization of flow cytometry sample prep can help deliver CAR-T therapies: https://lnkd.in/eF-jdm7S #DanaherAtWork #DanaherLifeSciences #CellTherapy #CART #FlowCytometry

This September, the spotlight's on #BloodCancer. Explore the cutting-edge journey of Dr. Mohamed Kharfan-Dabaja with CAR-T cell therapy. Discover hope in every breakthrough! Read more here: https://buff.ly/3Ldpwzb #CancerResearch #InnovationInAction #bloodcancerawarenessmonth

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy 🧠 #CancerEducation 🎓 #ImmunoOncology 🔴 #CancerTreatment #Genetherapy #CellTherapy 🔖 #MedLearn #NHS